大健康國際(02211.HK)擬折讓約4.93%增發7726.27萬股 淨籌1020萬港元
格隆匯10月29日丨大健康國際(02211.HK)公吿,於2021年10月29日,公司(作為發行人)與各名認購人(作為認購人)訂立認購協議,內容有關合共77,262,689股認購股份的認購事項,認購價為每股認購股份0.135港元。各項認購事項的認購價為0.135港元,較股份於2021年10月29日(即緊接認購協議日期前的最後交易日)在聯交所所報的收市價每股股份0.142港元折讓約4.93%。
認購事項的估計所得款項淨額(經扣除開支)將約為1020萬港元。公司擬將有關所得款項淨額用作本集團一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.